Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acceptability and Therapeutic Maintenance of the Biosimilar Ustekinumab After Substitution

NCT07077681 is registered in ClinicalTrials.gov with EG Labo as lead sponsor.

NCT NCT07077681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acceptability and Therapeutic Maintenance of the Biosimilar Ustekinumab After Substitution
Lead sponsor
EG Labo
Phase
Observational
Overall status
Recruiting
Start date
June 2, 2025
Completion date
December 31, 2027
Enrollment
246 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd)